Biostar Pharmaceuticals, Inc. (BSPM) Is At $1.99 Formed Wedge; Last Week Kinaxis Inc. (TSE:KXS) Coverage

Among 9 analysts covering Kinaxis Inc (TSE:KXS), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Kinaxis Inc had 38 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, August 7 by National Bank Canada. TD Securities maintained the shares of KXS in report on Friday, December 16 with “Buy” rating. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, November 18 report. RBC Capital Markets maintained the shares of KXS in report on Monday, October 31 with “Outperform” rating. The company was maintained on Friday, June 17 by Scotia Capital. On Friday, November 18 the stock rating was maintained by Scotia Capital with “Sector Perform”. The company was maintained on Friday, November 4 by Scotia Capital. The stock of Kinaxis Inc. (TSE:KXS) has “Buy” rating given on Thursday, March 2 by TD Securities. The stock of Kinaxis Inc. (TSE:KXS) has “Outperform” rating given on Monday, October 17 by BMO Capital Markets. The firm has “Outperform” rating by RBC Capital Markets given on Monday, February 27. See Kinaxis Inc. (TSE:KXS) latest ratings:

17/08/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $95.00 New Target: $82.00 Target Down
17/08/2017 Broker: Canaccord Genuity Old Rating: Buy New Rating: Hold Old Target: $100.00 New Target: $75.00 Target Up
17/08/2017 Broker: IBC Old Rating: Outperform New Rating: Neutral Old Target: $100.00 New Target: $82.00 Downgrade
17/08/2017 Broker: Eight Capital Rating: Buy Old Target: $100.00 New Target: $90.00 Target Up
17/08/2017 Broker: Laurentian Rating: Hold Old Target: $96.00 New Target: $83.00 Target Down
17/08/2017 Broker: National Bank Canada Rating: Outperform Old Target: $100.00 New Target: $90.00 Target Up
17/08/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: $100.00 New Target: $85.00 Target Up
17/08/2017 Broker: Scotia Capital Rating: Sector Perform Old Target: $87.00 New Target: $82.00 Target Down
17/08/2017 Broker: TD Securities Rating: Buy Old Target: $98.00 New Target: $93.00 Target Down

Biostar Pharmaceuticals, Inc. (BSPM) formed wedge up with $2.11 target or 6.00% above today’s $1.99 share price. Biostar Pharmaceuticals, Inc. (BSPM) has $5.25 million valuation. The stock decreased 5.69% or $0.12 during the last trading session, reaching $1.99. About 109,404 shares traded. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has risen 57.27% since January 9, 2017 and is uptrending. It has outperformed by 40.57% the S&P500.

The stock decreased 0.43% or $0.33 during the last trading session, reaching $77. About 74,890 shares traded. Kinaxis Inc. (TSE:KXS) has 0.00% since January 9, 2017 and is . It has underperformed by 16.70% the S&P500.

Kinaxis Inc. provides cloud-based software for supply chain operations. The company has market cap of $1.96 billion. The firm offers RapidResponse, which provides supply chain planning and analytics capabilities for managing various supply chain management processes, including demand planning, supply planning, inventory management, order fulfillment, and capacity planning. It has a 123.99 P/E ratio. It also offers professional services, such as implementation, technical, and training services, as well as maintenance and support services to its software products.